Overview

Olaparib's cross-border distribution is governed by stringent PARP-inhibitor regulations, so each 150 mg tablet batch must ship with a valid certificate of analysis, GMP attestation, and alignment to the importing territory's marketing authorization. Compliance documentation, not price, is usually the deciding factor for qualified buyers. The 60-tablet pack supports a two-tablet twice-daily course, and importers should confirm that labeling, serialization, and patient-leaflet language match local requirements before the goods move. Documentation integrity protects both patient and distributor.

How It Works

Olaparib is a potent inhibitor of PARP-1 and PARP-2, enzymes that repair single-strand DNA breaks. In tumors carrying BRCA1 or BRCA2 mutations, homologous recombination is already defective; blocking PARP tips cells into catastrophic, unrepairable DNA damage and cell death—a synthetic-lethal interaction. This mechanism is precisely why regulatory review focuses on confirming biomarker status and on consistent manufacturing quality, since potency is high and process impurities could shift the therapeutic index. The 150 mg strength enables flexible twice-daily assembly of the 300 mg target.

Indications

Olaparib is approved for BRCA-mutant ovarian, breast, pancreatic, and prostate cancers across several lines and settings, including maintenance after platinum chemotherapy. Eligibility requires confirmed germline or somatic BRCA mutation testing. Because the label is biomarker-defined, market access hinges on diagnostic availability and on the territory's approval of each specific indication. Therapy is typically continuous while benefit and tolerability persist.

Dosage & Administration

The usual oral dose is 300 mg twice daily, taken as two 150 mg tablets roughly 12 hours apart, with or without food. Capsule or tablet forms are not substituted arbitrarily. Dose holds or reductions follow labeled rules for hematologic toxicity. Procurement should match the 60-tablet pack to a one-month twice-daily course to keep the supply calendar aligned with the treatment rhythm.

Storage & Sourcing

Keep tablets at 2–8 °C or up to 25 °C in the original blister, away from moisture and light. Each imported batch must arrive with COA, GMP certificate, and the territory authorization reference, with cold-chain logged. Verify serialization and expiry on receipt, rotate by earliest expiry, and retain the compliance folder for audit. Quarantine any pack failing documentation checks before dispensing.

FAQ

Q: What regulatory documents must accompany an olaparib shipment?

A: A certificate of analysis, GMP certificate, batch-release record, and the importing territory's marketing-authorization or import permit reference should travel with every batch.

Q: Is olaparib approved identically across all importing markets?

A: No; each territory approves specific BRCA-related indications and lines, so confirm that the intended use is authorized where the product will be dispensed before supply.

Q: How does a buyer confirm batch GMP and COA authenticity?

A: Cross-check the batch number on the carton against the COA and GMP certificate, validate the manufacturer identifier, and where available confirm against the regulator's serialization database.

Q: What labeling requirements apply to PARP-inhibitor exports?

A: Labels must show strength, batch, expiry, and local-language warnings, plus serial or barcode identifiers per the destination market's track-and-trace rules.